Subscribe To
SBTX / Goldman Sachs Has 5 Buy-Rated Stocks Under $10 With 100% to 600% Upside Potential
SBTX News
By Benzinga
April 1, 2022
Silverback Therapeutics Axes Lead Immuno-Oncology Candidates, Lays Off 27% Workforce
Silverback Therapeutics Inc (NASDAQ: SBTX) undertakes “strategic realignment,” revealing it would drop its two lead cancer programs and lays of more_horizontal
By GeekWire
March 31, 2022
Silverback Therapeutics shuts down oncology program, plans to lay off 27% of workforce
Silverback Therapeutics will lay off 27% of its workforce and close its oncology program, the Seattle company announced Thursday in its fourth quarter more_horizontal
By 24/7 Wall Street
February 19, 2022
Goldman Sachs Has 5 Buy-Rated Stocks Under $10 With 100% to 600% Upside Potential
While most of Wall Street focuses on large-cap and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in th more_horizontal
By 24/7 Wall Street
February 19, 2022
Goldman Sachs Has 5 Buy-Rated Stocks Under $10 With 100% to 600% Upside Potential
While most of Wall Street focuses on large-cap and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in th more_horizontal
By 24/7 Wall Street
February 19, 2022
Goldman Sachs Has 5 Buy-Rated Stocks Under $10 With 100% to 600% Upside Potential
While most of Wall Street focuses on large-cap and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in th more_horizontal